Results 111 to 120 of about 420,256 (310)

Dual targeting of RET and SRC synergizes in RET fusion‐positive cancer cells

Molecular Oncology, EarlyView.
Despite the strong activity of selective RET tyrosine kinase inhibitors (TKIs), resistance of RET fusion‐positive (RET+) lung cancer and thyroid cancer frequently occurs and is mainly driven by RET‐independent bypass mechanisms. Son et al. show that SRC TKIs significantly inhibit PAK and AKT survival signaling and enhance the efficacy of RET TKIs in ...
Juhyeon Son, Lily L. Remsing Rix, Bin Fang, Eric A. Welsh, Nicole V. Bremer, Valentina Foglizzo, Paola Roa, Nickole Sigcha‐Coello, Yi Liao, Eric B. Haura, Alexander Drilon, John M. Koomen, Emiliano Cocco, Uwe Rix   +13 more
wiley   +1 more source

Review of medicine registration system in Tanzania [PDF]

, 2019
Philosophiae Doctor - PhDRegistration of medicines is an essential function of the national medicine regulatory system of any country. Since the start of the medicine registration system in Tanzania in early 2000s, no systematic review has been carried
KISOMA, SUNDAY
core  

Next‐generation proteomics improves lung cancer risk prediction

Molecular Oncology, EarlyView.
This is one of very few studies that used prediagnostic blood samples from participants of two large population‐based cohorts. We identified, evaluated, and validated an innovative protein marker model that outperformed an established risk prediction model and criteria employed by low‐dose computed tomography in lung cancer screening trials.
Megha Bhardwaj, Clara Frick, Ben Schöttker, Bernd Holleczek, Hermann Brenner   +4 more
wiley   +1 more source

KETOPROFEN: APPLICATION AND DOSAGE FORMS

Разработка и регистрация лекарственных средств, 2019
Ketoprofen is a medicinal substance that has not lost its relevance in modern medicine and pharmacy. The article describes the aspects of its application. The prospects of creating new dosage forms containing ketoprofen are considered. The possibility of
A. V. Belyatskaya, I. I. Krasnyuk (Jr.), I. I. Krasnyuk, T. E. Machikina, Yu. A. Korosteleva, O. I. Stepanova, I. M. Kashlikova, Y. V. Skovpen, A. N. Vorob'yov   +8 more
doaj  

A critical comparison between dosage forms in traditional Persian pharmacy and those reported in current pharmaceutical sciences [PDF]

Research Journal of Pharmacognosy, 2017
There were many natural pharmaceutical dosage forms cited by Persian pharmacists and physicians in the historical pharmacopeias (Qarabadins). This work aimed to perform a comprehensive study on “Qarābādin-e-Sālehi” (1765 A.D.), one of the main Persian ...
M. Baranifard, M.M. Khazaei, S. Jamshidi, M.M. Zarshenas, A. Zargaran   +4 more
doaj  

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

Molecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak, Karolina Pytlak, Sandra Jaworowska, Bogusz Kulawiak, Piotr Bednarczyk   +4 more
wiley   +1 more source

Ayurvedic Dosage Forms: Pressing Priorities and Challenges therein with Respect to Solid and Semisolid Oral Dosage Forms

Indian Journal of Ayurveda and Integrative Medicine KLEU
Continuous improvements in elevating traditional dosage forms to increase therapeutic efficacy, to enable patient-centric approaches, and to improve patient compliance are becoming more rational with advancements in technology and an advanced vision to ...
Sakshi Badyal, Poonam Dang, Puneet Dhawan, Himanshu Shekhar Tiwari   +3 more
doaj   +1 more source

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

Molecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet   +17 more
wiley   +1 more source

Development and Validation of a Rapid and Sensitive Ultrahigh-Performance Liquid Chromatography with Diode Array Detection Method for Quantification of Sertraline in Pharmaceutical Formulations

Pharmata
Objective: This study aimed to develop and validate a new, sensitive, fast, and simple ultrahighperformance liquid chromatography (UHPLC) method for the quantification of sertraline in pharmaceutical preparations and then apply it to commercial ...
Tuğrul Çağrı Akman, Mahmut Can Bebek
doaj   +1 more source

Exploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells

Molecular Oncology, EarlyView.
We show that dabrafenib‐resistant melanoma cells undergo mitochondrial remodeling, leading to elevated respiration and ROS production balanced by stronger antioxidant defenses. This altered redox state promotes survival despite mitochondrial damage but renders resistant cells highly vulnerable to ROS‐inducing compounds such as PEITC, highlighting redox
Silvia Eller, Susanne Ebner, Carmen Haselrieder, Julia K. Günther, Astrid Drasche, Sophie Strich, Chiara Volani, Andrea Medici, Aleksandar Nikolajevic, Alex Deltedesco, Johannes E. Sigmund, Michael J. Blumer, Martin Hermann, Johanna Vanacker, Gerald Brandacher, Eduard Stefan, Omar Torres‐Quesada, Jakob Troppmair   +17 more
wiley   +1 more source